QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
Free Trial
ASX:MEM

Memphasys (MEM) Stock Price, News & Analysis

→ Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad)
Free MEM Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
246,322 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.20%
Price Target
N/A
Stock Analysis
Stock Analysis
MEM stock logo

About Memphasys Stock (ASX:MEM)

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

MEM Stock News Headlines

May 22, 2023 | hk.finance.yahoo.com
Memphasys Reaches AU$20m Market Cap Benefiting Insider Stock Buying
May 20, 2023 | finance.yahoo.com
Memphasys Reaches AU$20m Market Cap Benefiting Insider Stock Buying \
April 18, 2024 | GoldenCrest Metals (Ad)
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
April 5, 2023 | afr.com
Blood pressure rises at Aegros, the next plasma hopeful
April 2, 2023 | msn.com
Dr Boreham’s Crucible: Every sperm is sacred – and profitable
March 9, 2023 | finance.yahoo.com
Memphasys Limited (IG7.F)
February 25, 2023 | finance.yahoo.com
Memphasys First Half 2023 Earnings: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2022)
February 23, 2023 | marketwatch.com
Research Insight View on Centrifugation-free Sperm Separation Systems Market Size [2023-2028] | Emerging Trend and Current Developments
April 18, 2024 | GoldenCrest Metals (Ad)
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
February 6, 2023 | msn.com
ASX Health Stocks: Creso eyes psychedelic spinout off the back of landmark TGA decision
December 11, 2022 | finance.yahoo.com
A Memphasys Limited (ASX:MEM) insider increased their holdings by 6.2% last year
July 27, 2022 | afr.com
Placement outbreak: Creso Pharma, New World, Memphasys chase investors
June 9, 2022 | msn.com
ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac
March 20, 2022 | proactiveinvestors.com.au
Memphasys achieves quality certification for medical devices and diagnostics
January 26, 2022 | proactiveinvestors.com.au
Memphasys outlines vision for biological separation tech in 2022
December 8, 2021 | msn.com
Standouts: 3 ASX biotech shares that outperformed in November
December 7, 2021 | au.finance.yahoo.com
Memphasys Limited (MEM.AX)
November 16, 2021 | msn.com
These 3 ASX healthcare shares are soaring today. Why?
November 2, 2021 | msn.com
ASX Health Stocks: Paradigm rockets 21pc after getting FDA nod, Memphasys up 31pc on imminent launch
July 29, 2021 | fool.com.au
Ellume is making news and these ASX shares are surging, again
July 28, 2021 | msn.com
When Ellume is making news, these ASX shares are in focus
See More Headlines
Receive MEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Memphasys and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:MEM
CUSIP
N/A
CIK
N/A
Web
www.memphasys.com
Phone
61 2 8415 7300
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,520,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-55.98%
Return on Assets
-16.93%

Debt

Debt-to-Equity Ratio
83.82
Current Ratio
0.17
Quick Ratio
0.39

Sales & Book Value

Annual Sales
$81,148.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
12.20
Book Value
A$0.01 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,370,000,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.72
10 Best Stocks to Own in 2024 Cover
10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. David Ali
    Acting CEO & Executive Director
  • Pablo Neyertz
    Director of Finance
  • Associate Prof. Hassan Bakos
    Director of Operations
  • Prof. R. John Aitken Ph.D.
    ScD FRSE, Scientific Director
  • Mr. Andrew Metcalfe B.Bus
    CPA, FGIA, MAICD, Company Secretary

Key Competitors

View All Competitors

This page (ASX:MEM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Biden’s $374B Giveaway Into This Sector
DTI
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
He Is Giving Away Bitcoin
Crypto Swap Profits